Interleukin-6 mediates resistance to PI3K-pathway–targeted therapy in lymphoma

BACKGROUND: The phosphoinositol 3-kinase (PI3K) pathway is associated with poor prognosis of hematologic malignancies, providing a strong rationale for the use of PI3K inhibitors in the treatment of malignant lymphoma. However, development of resistance limits the use of PI3K inhibitors in lymphoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Joo Hyun, Kim, Won Seog, Park, Chaehwa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785854/
https://www.ncbi.nlm.nih.gov/pubmed/31601188
http://dx.doi.org/10.1186/s12885-019-6057-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785854/
https://www.ncbi.nlm.nih.gov/pubmed/31601188
http://dx.doi.org/10.1186/s12885-019-6057-7

Ejemplares similares